Acumen's Q2 Cash Drops to $110M, ALTITUDE-AD Topline Data Due Late 2026
ABOS has more than doubled off its 52-week low of $1.19.
Summary
Acumen reported Q2 2026 financials with cash declining to $110.2M from $128.4M at Q1-end, providing runway into early 2027. R&D expenses fell to $27.8M from $37.1M a year ago, driving a narrower net loss of $32.7M. The company reiterated that topline results from the pivotal ALTITUDE-AD Phase 2 trial of sabirnetug in early Alzheimer's are expected late 2026. Two EBD candidates, ACU301 and ACU401, were nominated in June, with IND submission targeted for mid-2027. The cash burn rate and upcoming binary catalyst make this a critical period for the company.
At the time of this announcement, ABOS was trading at $2.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $178.4M. The 52-week trading range was $1.19 to $3.60. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.